Longitudinal Assessment of Ductus Venosus Doppler Parameters and Their Association With Perinatal Outcomes in Pregnancies With Intrauterine Growth Restriction

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This prospective observational cohort study aims to evaluate the relationship between ductus venosus Doppler parameters and perinatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR). Pregnant women diagnosed with IUGR will undergo longitudinal Doppler assessments of the ductus venosus during the third trimester. The Doppler indices will be correlated with perinatal outcomes, including Apgar scores, neonatal intensive care unit (NICU) admission, and perinatal mortality. The study seeks to determine whether serial ductus venosus Doppler measurements can serve as predictive markers of adverse neonatal outcomes in IUGR pregnancies.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: f
View:

• Female participants aged 18-45 years

• Singleton pregnancy

• Intrauterine growth restriction (IUGR) with estimated fetal weight \<10th percentile for gestational age

• Gestational age ≥24 weeks at enrollment

• Ability to comply with scheduled follow-up visits and Doppler examinations

• Signed informed consent obtained

Locations
Other Locations
Turkey
Izmir City Hospital
RECRUITING
Izmir
Contact Information
Primary
ILAYDA GERCIK ARZIK, MD
ilgercik@gmail.com
+905556124197
Backup
Hale Ankara Aktas, MD
haleankara@gmail.com
+905415470595
Time Frame
Start Date: 2025-09-01
Estimated Completion Date: 2026-03-01
Participants
Target number of participants: 81
Treatments
IUGR Pregnancies
Pregnant women diagnosed with intrauterine growth restriction will be followed longitudinally with serial ductus venosus Doppler assessments during the third trimester. Perinatal outcomes will be recorded until delivery and the early neonatal period.
Related Therapeutic Areas
Sponsors
Leads: İlayda Gercik Arzık, MD

This content was sourced from clinicaltrials.gov